Related Experiment Video
Updated: Jan 30, 2026

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
Novel role of microRNA-126 in digestive system cancers: From bench to bedside
Mingli Hu1, Shengwei Xiong1, Qiaofeng Chen1
1Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330000, P.R. China.
Abstract:
MicroRNAs (miRNAs) are ubiquitously expressed, small, non-coding RNAs that regulate the expression of approximately 30% of the human genes at the post-transcriptional level. miRNAs have emerged as crucial modulators in the initiation and progression of various diseases, including numerous cancer types. The high incidence rate of cancer and the large number of cancer-associated cases of mortality are mostly due to a lack of effective treatments and biomarkers for early diagnosis. Therefore there is an urgent requirement to further understand the underlying mechanisms of tumorigenesis. MicroRNA-126 (miR-126) is significantly downregulated in a number of tumor types and is commonly identified as a tumor suppressor in digestive system cancers (DSCs). miR-126 downregulates various oncogenes, including disintegrin and metalloproteinase domain-containing protein 9, v-crk sarcoma virus CT10 oncogene homolog and phosphoinositide-3-kinase regulatory subunit 2. These genes are involved in a number of tumor-associated signaling pathways, including angiogenesis, epithelial-mensenchymal transition and metastasis pathways. The aim of the current review was to summarize the role of miR-126 in DSCs, in terms of its dysregulation, target genes and associated signaling pathways. In addition, the current review has discussed the potential clinical application of miR-126 as a biomarker and therapeutic target for DSCs.
Insights
MicroRNA-126 (miR-126) acts as a tumor suppressor in digestive system cancers by downregulating oncogenes. Its reduced levels indicate potential as a diagnostic biomarker and therapeutic target for these cancers.
Area of Science:
- Molecular Biology
- Genetics
- Oncology
Background:
- MicroRNAs (miRNAs) are small, non-coding RNAs regulating gene expression post-transcriptionally.
- miRNAs are critical in disease development, including various cancers, necessitating research into tumorigenesis mechanisms.
- Effective cancer treatments and early diagnostic biomarkers are lacking, highlighting the need for further understanding.
Purpose of the Study:
- To review the role of microRNA-126 (miR-126) in digestive system cancers (DSCs).
- To summarize miR-126's dysregulation, target genes, and associated signaling pathways in DSCs.
- To discuss the potential clinical applications of miR-126 as a biomarker and therapeutic target for DSCs.
Main Methods:
- Literature review summarizing existing research on miR-126 in DSCs.
- Analysis of miR-126's regulatory functions on specific oncogenes.
- Examination of signaling pathways influenced by miR-126, such as angiogenesis, epithelial-mesenchymal transition, and metastasis.
Main Results:
- MicroRNA-126 (miR-126) is frequently downregulated in several tumor types and acts as a tumor suppressor in DSCs.
- miR-126 targets and downregulates oncogenes like disintegrin and metalloproteinase domain-containing protein 9, v-crk sarcoma virus CT10 oncogene homolog, and phosphoinositide-3-kinase regulatory subunit 2.
- These targeted oncogenes are implicated in critical tumor-associated signaling pathways.
Conclusions:
- miR-126 plays a significant tumor-suppressive role in DSCs.
- Dysregulation of miR-126 impacts key oncogenic pathways.
- miR-126 holds promise as a potential biomarker for early diagnosis and a therapeutic target for DSCs.
Related Concept Videos
MicroRNAs
MicroRNAs
Carbohydrate Digestion
What is Monogastric Digestion?
Lipid Digestion
Protein Digestion

